Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Neupath Health Inc. ( (TSE:NPTH) ).
NeuPath Health Inc. has announced a planned leadership transition that will see President Stephen Lemieux take over as Chief Executive Officer on April 1, 2026, succeeding Joseph Walewicz, who will remain on the board and act in a consulting capacity, while the company also elevates Sandee Dela Cruz to the newly created role of Chief Information Officer to strengthen its IT strategy in support of growth. Alongside these changes, NeuPath pre-announced strong preliminary fiscal 2025 results, projecting revenue between $86 million and $88 million and Adjusted EBITDA of $5.6 million to $6.0 million, up from 2024, signalling continued operational momentum and underpinning the board’s confidence in the new leadership team to execute the company’s growth strategy.
The most recent analyst rating on (TSE:NPTH) stock is a Buy with a C$0.50 price target. To see the full list of analyst forecasts on Neupath Health Inc. stock, see the TSE:NPTH Stock Forecast page.
More about Neupath Health Inc.
NeuPath Health Inc., listed on the TSX Venture Exchange, operates in the healthcare sector with a focus on pain management and related health services, leveraging clinic networks and technology capabilities to expand its presence across Canada, including Western Canada following its acquisition of HealthPointe in 2021.
Average Trading Volume: 185,132
Technical Sentiment Signal: Buy
Current Market Cap: C$30.47M
See more data about NPTH stock on TipRanks’ Stock Analysis page.